Collagen inhibits phagocytosis of amyloid in vitro and in vivo and may act as a ‘don’t eat me’ signal

References

• Merlini G. Systemic amyloidosis: are we moving ahead? Neth J Med. 2004;62(4):104–105.
   PubMed Web of Science ®Google Scholar
• Gertz MA, Dispenzieri A. Systemic amyloidosis recognition, prognosis, and therapy: a systematic review. JAMA. 2020; Jul 7324(1):79–89.
   PubMed Web of Science ®Google Scholar
• Benson MD, Buxbaum JN, Eisenberg DS, et al. Amyloid nomenclature 2020: update and recommendations by the international society of amyloidosis (ISA) nomenclature committee. Amyloid. 2020;27(4):217–222.
   PubMed Web of Science ®Google Scholar
• Merlini G, Bellotti V. Molecular mechanisms of amyloidosis. N Engl J Med. 2003;349(6):583–596.
   PubMed Web of Science ®Google Scholar
• Wechalekar AD, Gillmore JD, Hawkins PN. Systemic amyloidosis. Lancet. 2016;387(10038):2641–2654.
   PubMed Web of Science ®Google Scholar
• Barrett CD, Dobos K, Liedtke M, et al. A changing landscape of mortality for systemic light chain amyloidosis. JACC Heart Fail. 2019;7(11):958–966.
   PubMed Web of Science ®Google Scholar
• Muchtar E, Gertz MA, Kumar SK, et al. Improved outcomes for newly diagnosed AL amyloidosis between 2000 and 2014: cracking the glass ceiling of early death. Blood. 2017;129(15):2111–2119.
   PubMed Web of Science ®Google Scholar
• Al Hamed R, Bazarbachi AH, Bazarbachi A, et al. Comprehensive review of AL amyloidosis: some practical recommendations. Blood Cancer J. 2021;11(5):97.
   PubMed Web of Science ®Google Scholar
• Palladini G, Merlini G. Current treatment of AL amyloidosis. Haematologica. 2009;94(8):1044–1048.
   PubMed Web of Science ®Google Scholar
• Bianchi G, Zhang Y, Comenzo RL. AL amyloidosis: current chemotherapy and immune therapy treatment strategies: JACC: cardiooncology state-of-the-art review. JACC CardioOncol. 2021;3(4):467–487.
   PubMedGoogle Scholar
• Shragai T, Gatt M, Lavie N, et al. Daratumumab for relapsed AL amyloidosis—when cumulative real‐world data precedes clinical trials: a multisite study and systematic literature review. Eur J Haematol. 2021;106(2):184–195.
   PubMed Web of Science ®Google Scholar
• Blair JE, Zeigler SM, Mehta J, et al. Regression of cardiac amyloid after autologous stem-cell transplantation. J Heart Lung Transplant. 2009;28(7):746–748.
   PubMed Web of Science ®Google Scholar
• Hawkins PN, Richardson S, MacSweeney JE, et al. Scintigraphic quantification and serial monitoring of human visceral amyloid deposits provide evidence for turnover and regression. Q J Med. 1993;86(6):365–374.
   PubMedGoogle Scholar
• Holmgren G, Ericzon BG, Groth CG, et al. Clinical improvement and amyloid regression after liver transplantation in hereditary transthyretin amyloidosis. Lancet. 1993;341(8853):1113–1116.
   PubMed Web of Science ®Google Scholar
• Pepys MB, Gallimore JR, Lloyd J, et al. Isolation and characterization of pharmaceutical grade human pentraxins, serum amyloid P component and C-reactive protein, for clinical use. J Immunol Methods. 2012;384(1-2):92–102.
   PubMed Web of Science ®Google Scholar
• Higaki JN, Chakrabartty A, Galant NJ, et al. Novel conformation-specific monoclonal antibodies against amyloidogenic forms of transthyretin. Amyloid. 2016;23(2):86–97.
   PubMed Web of Science ®Google Scholar
• Michalon A, Hagenbuch A, Huy C, et al. A human antibody selective for transthyretin amyloid removes cardiac amyloid through phagocytic immune cells. Nat Commun. 2021;12(1):3142.
   PubMed Web of Science ®Google Scholar
• Foster JS, Williams AD, Macy S, et al. A peptide-Fc opsonin with pan-amyloid reactivity. Front Immunol. 2017;8:1082.
   PubMed Web of Science ®Google Scholar
• Edwards CV, Gould J, Langer AL, et al. Interim analysis of the phase 1a/b study of chimeric fibril-reactive monoclonal antibody 11-1F4 in patients with AL amyloidosis. Amyloid. 2017;24(sup1):58–59.
   PubMed Web of Science ®Google Scholar
• Gertz MA, Landau H, Comenzo RL, et al. First-in-human phase I/II study of NEOD001 in patients with light chain amyloidosis and persistent organ dysfunction. J Clin Oncol. 2016;34(10):1097–1103.
   PubMed Web of Science ®Google Scholar
• Richards DB, Cookson LM, Berges AC, et al. Therapeutic clearance of amyloid by antibodies to serum amyloid P component. N Engl J Med. 2015;373(12):1106–1114.
   PubMed Web of Science ®Google Scholar
• Richey T, Foster JS, Williams AD, et al. Macrophage-mediated phagocytosis and dissolution of amyloid-like fibrils in mice, monitored by optical imaging. Am J Pathol. 2019;189(5):989–998.
   PubMed Web of Science ®Google Scholar
• Wall JS, Williams AD, Foster JS, et al. Bifunctional amyloid-reactive peptide promotes binding of antibody 11-1F4 to diverse amyloid types and enhances therapeutic efficacy. Proc Natl Acad Sci U S A. 2018;115(46):E10839–E10848.
   PubMed Web of Science ®Google Scholar
• Vrana JA, Theis JD, Dasari S, et al. Clinical diagnosis and typing of systemic amyloidosis in subcutaneous fat aspirates by mass spectrometry-based proteomics. Haematologica. 2014;99(7):1239–1247.
   PubMed Web of Science ®Google Scholar
• Milde R, Ritter J, Tennent GA, et al. Multinucleated giant cells are specialized for complement-mediated phagocytosis and large target destruction. Cell Rep. 2015;13(9):1937–1948.
   PubMed Web of Science ®Google Scholar
• Hrncic R, Wall J, Wolfenbarger DA, et al. Antibody-mediated resolution of light chain-associated amyloid deposits. Am J Pathol. 2000;157(4):1239–1246.
   PubMed Web of Science ®Google Scholar
• Lund ME, To J, O'Brien BA, et al. The choice of phorbol 12-myristate 13-acetate differentiation protocol influences the response of THP-1 macrophages to a pro-inflammatory stimulus. J Immunol Methods. 2016;430:64–70.
   PubMed Web of Science ®Google Scholar
• Little AC, Pathanjeli P, Wu Z, et al. IL-4/IL-13 stimulated macrophages enhance breast cancer invasion via Rho-GTPase regulation of synergistic VEGF/CCL-18 signaling. Front Oncol. 2019;9:456.
   PubMed Web of Science ®Google Scholar
• Liu L, Guo H, Song A, et al. Progranulin inhibits LPS-induced macrophage M1 polarization via NF-small ka, CyrillicB and MAPK pathways. BMC Immunol. 2020;21(1):32.
   PubMed Web of Science ®Google Scholar
• Lundahl MLE, Mitermite M, Ryan DG, et al. Macrophage innate training induced by IL-4 and IL-13 activation enhances OXPHOS driven anti-mycobacterial responses. Elife. 2022;11:22–24.
   Web of Science ®Google Scholar
• Wall J, Schell M, Murphy C, et al. Thermodynamic instability of human lambda 6 light chains: correlation with fibrillogenicity. Biochemistry. 1999;38(42):14101–14108.
   PubMed Web of Science ®Google Scholar
• Pras M, Schubert M, Zucker-Franklin D, et al. The characterization of soluble amyloid prepared in water. J Clin Invest. 1968;47(4):924–933.
   PubMed Web of Science ®Google Scholar
• Nelson ME, Fiatarone MA, Layne JE, et al. Analysis of body-composition techniques and models for detecting change in soft tissue with strength training. Am J Clin Nutr. 1996;63(5):678–686.
   PubMed Web of Science ®Google Scholar
• Obici L, Perfetti V, Palladini G, et al. Clinical aspects of systemic amyloid diseases. Biochim Biophys Acta. 2005;1753(1):11–22.
   PubMed Web of Science ®Google Scholar
• Kristen AV, Brokbals E, Aus Dem Siepen F, et al. Cardiac amyloid load: a prognostic and predictive biomarker in patients with Light-Chain amyloidosis. J Am Coll Cardiol. 2016;68(1):13–24.
   PubMed Web of Science ®Google Scholar
• Banypersad SM, Fontana M, Maestrini V, et al. T1 mapping and survival in systemic light-chain amyloidosis. Eur Heart J. 2015;36(4):244–251.
   PubMed Web of Science ®Google Scholar
• Kuroda T, Tanabe N, Kobayashi D, et al. Significant association between renal function and amyloid-positive area in renal biopsy specimens in AL amyloidosis. BMC Nephrol. 2012;13:118.
   PubMed Web of Science ®Google Scholar
• Kuroda T, Tanabe N, Kobayashi D, et al. Significant association between renal function and area of amyloid deposition in kidney biopsy specimens in reactive amyloidosis associated with rheumatoid arthritis. Rheumatol Int. 2012;32(10):3155–3162.
   PubMed Web of Science ®Google Scholar
• Van Gameren II, Van Rijswijk MH, Bijzet J, et al. Histological regression of amyloid in AL amyloidosis is exclusively seen after normalization of serum free light chain. Haematologica. 2009;94(8):1094–1100.
   PubMed Web of Science ®Google Scholar
• Katoh N, Matsuda M, Tsuchiya‐Suzuki A, et al. Regression of gastroduodenal amyloid deposition in systemic AL amyloidosis after intensive chemotherapies. Br J Haematol. 2011;153(4):535–538.
   PubMed Web of Science ®Google Scholar
• Lovat LB, Persey MR, Madhoo S, et al. The liver in systemic amyloidosis: insights from 123I serum amyloid P component scintigraphy in 484 patients. Gut. 1998;42(5):727–734.
   PubMed Web of Science ®Google Scholar
• Katoh N, Matsushima A, Kurozumi M, et al. Marked and rapid regression of hepatic amyloid deposition in a patient with systemic light chain (AL) amyloidosis after high-dose melphalan therapy with stem cell transplantation. Intern Med. 2014;53(17):1991–1995.
   PubMed Web of Science ®Google Scholar
• Fitzgerald BT, Bashford J, Scalia GM. Regression of the anatomic cardiac features of amyloid light chain cardiac amyloidosis accompanied by normalization of global longitudinal strain. CASE. 2017;1(2):46–48.
   PubMedGoogle Scholar
• O'Nuallain B, Hrncic R, Wall JS, et al. Diagnostic and therapeutic potential of amyloid-reactive IgG antibodies contained in human sera. J Immunol. 2006;176(11):7071–7078.
   PubMed Web of Science ®Google Scholar
• Tarasoff-Conway JM, Carare RO, Osorio RS, et al. Clearance systems in the brain—implications for Alzheimer disease. Nat Rev Neurol. 2015;11(8):457–470.
   PubMed Web of Science ®Google Scholar
• Greenberg SM, Bacskai BJ, Hernandez-Guillamon M, et al. Cerebral amyloid angiopathy and Alzheimer disease — one peptide, two pathways. Nat Rev Neurol. 2020;16(1):30–42.
   PubMed Web of Science ®Google Scholar
• Coraci IS, Husemann J, Berman JW, et al. CD36, a class B scavenger receptor, is expressed on microglia in Alzheimer’s disease brains and can mediate production of reactive oxygen species in response to β-amyloid fibrils. Am J Pathol. 2002;160(1):101–112.
   PubMed Web of Science ®Google Scholar
• Dobri A-M, Dudău M, Enciu A-M, et al. CD36 in Alzheimer’s disease: an overview of molecular mechanisms and therapeutic targeting. Neuroscience. 2021;453:301–311.
   PubMed Web of Science ®Google Scholar
• Knopman DS, Amieva H, Petersen RC, et al. Alzheimer disease. Nat Rev Dis Primers. 2021;7(1):33.
   PubMed Web of Science ®Google Scholar
• Srivastava S, Ahmad R, Khare SK. Alzheimer’s disease and its treatment by different approaches: a review. Eur J Med Chem. 2021;216:113320.
   PubMed Web of Science ®Google Scholar
• Sethi S, Vrana JA, Theis JD, et al. Laser microdissection and mass spectrometry-based proteomics aids the diagnosis and typing of renal amyloidosis. Kidney Int. 2012;82(2):226–234.
   PubMed Web of Science ®Google Scholar
• Vrana JA, Gamez JD, Madden BJ, et al. Classification of amyloidosis by laser microdissection and mass spectrometry-based proteomic analysis in clinical biopsy specimens. Blood. 2009;114(24):4957–4959.
   PubMed Web of Science ®Google Scholar
• Kozlov VA, Sapozhnikov SP, Karyshev PB. Trichrome staining for detection of amyloid. Cell Tiss Biol. 2018;12(1):80–84.
   Google Scholar
• Hay DC, Louie DL, Earp BE, et al. Surgical findings in the treatment of Dupuytren’s disease after initial treatment with clostridial collagenase (Xiaflex). J Hand Surg Eur Vol. 2014;39(5):463–465.
   PubMed Web of Science ®Google Scholar
• Shin D, Shah T, Sadeghi-Nejad H. Xiaflex for treatment of Peyronie’s disease. Eur Urol Focus. 2018;4(3):302–303.
   PubMedGoogle Scholar